---
title: 'Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis:
  Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines
  Committee'
date: '2024-03-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38472477/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240313180649&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'Systemic Mastocytosis (SM) is a multifaceted clinically heterogeneous
  disease. Advanced SM (AdvSM) comprises three entities: aggressive SM (ASM), mast
  cell leukaemia (MCL) and SM with an associated hematologic neoplasm (SM-AHN), the
  latter accounting for 60-70% of all AdvSM cases. Detection of a disease-triggering
  mutation in the KIT gene (esp. KIT D816V) in >90% of the patients with ASM or SM-AHN
  has led to a significant improvement in therapeutic options by the implementation
  of ...'
disable_comments: true
---
Systemic Mastocytosis (SM) is a multifaceted clinically heterogeneous disease. Advanced SM (AdvSM) comprises three entities: aggressive SM (ASM), mast cell leukaemia (MCL) and SM with an associated hematologic neoplasm (SM-AHN), the latter accounting for 60-70% of all AdvSM cases. Detection of a disease-triggering mutation in the KIT gene (esp. KIT D816V) in >90% of the patients with ASM or SM-AHN has led to a significant improvement in therapeutic options by the implementation of ...